-
公开(公告)号:EP1756062A1
公开(公告)日:2007-02-28
申请号:EP05751010.9
申请日:2005-05-13
申请人: IRM LLC
发明人: EPPLE, Robert , AZIMIOARA, Mihai
IPC分类号: C07D215/00 , C07C53/132 , C07C69/00 , A61K31/19 , A61K31/215 , A61K31/47
CPC分类号: C07D215/14 , A61K31/19 , A61K31/215 , A61K31/47 , A61K45/06 , C07C59/68 , C07C59/70 , C07C217/76 , C07C255/54 , C07C317/22 , C07C323/19 , C07C323/20 , C07C323/62 , C07D213/28 , C07D213/61 , C07D215/12 , C07D239/26 , C07D307/40 , C07D307/80 , A61K2300/00
摘要: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ .
摘要翻译: 本发明提供了化合物,包含此类化合物的药物组合物以及使用此类化合物治疗或预防与过氧化物酶体增殖物激活受体(PPAR)家族的活性相关的疾病或病症,特别是PPARδ活性的方法。
-
公开(公告)号:EP3019034A2
公开(公告)日:2016-05-18
申请号:EP14734162.2
申请日:2014-07-01
申请人: Givaudan SA
发明人: BOM, David C.
IPC分类号: A23L27/20 , C07D409/12 , C07D213/16
CPC分类号: A23L27/2054 , A23L27/2056 , A23V2002/00 , C07D213/28 , C07D213/32
摘要: in which R1, R2, R3, R4 R5, R6 are independently selected from the group consisting of H, methyl, ethyl, propyl, OH, OMe, OEt, COOH, COOR7, in which R7 is selected from linear or branched C1-C7 alkyl, and CONR8R9, in which R8 and R9 are independently selected from hydrogen and straight or branched C1-C4 alkyl; or any two adjacent substituents R2-R6 together form a ring of 5 or 6 members; and n is 1 or 0.
摘要翻译: 一种赋予或改变可食用产品鲜味的方法,包括将至少一种式(I)化合物加入可食用产品基质中,其中X 1 X 2或X 3中的一个选自: 的S,N和O,其余两个是CH 2; 和A选自式(II)(III)和(IV)其中R 1 R 2 R 3 R 4 R 5 R 6独立地选自H,甲基,乙基,丙基,OH,OMe, OEt,COOH,COOR 7,其中R 7选自直链或支链C 1 -C 7烷基和CONR 8 R 9,其中R 8和R 9独立地选自氢和直链或支链C 1 -C 4 烷基; 或任何两个相邻的取代基R 2 -R 6一起形成5或6元环; 并且n是1或0。
-
公开(公告)号:EP1756062A4
公开(公告)日:2008-01-02
申请号:EP05751010
申请日:2005-05-13
申请人: IRM LLC
发明人: EPPLE ROBERT , AZIMIOARA MIHAI
IPC分类号: C07C59/68 , A61K31/19 , A61K31/215 , A61K31/47 , A61K45/06 , A61P35/00 , C07C53/132 , C07C59/70 , C07C69/00 , C07C217/76 , C07C255/54 , C07C317/22 , C07C323/19 , C07C323/20 , C07C323/62 , C07D213/28 , C07D213/61 , C07D215/00 , C07D215/12 , C07D215/14 , C07D239/26 , C07D307/40 , C07D307/80
CPC分类号: C07D215/14 , A61K31/19 , A61K31/215 , A61K31/47 , A61K45/06 , C07C59/68 , C07C59/70 , C07C217/76 , C07C255/54 , C07C317/22 , C07C323/19 , C07C323/20 , C07C323/62 , C07D213/28 , C07D213/61 , C07D215/12 , C07D239/26 , C07D307/40 , C07D307/80 , A61K2300/00
-
公开(公告)号:EP4433452A2
公开(公告)日:2024-09-25
申请号:EP22896465.6
申请日:2022-11-17
IPC分类号: C07D213/16 , C07D213/20 , H01M4/60 , H01M4/36 , H01M8/18
CPC分类号: C07D213/20 , C07D213/26 , C07D213/38 , C07D213/28 , H01M8/188
-
公开(公告)号:EP3019034B1
公开(公告)日:2018-10-31
申请号:EP14734162.2
申请日:2014-07-01
申请人: Givaudan SA
发明人: BOM, David C.
IPC分类号: A23L27/20 , C07D409/12 , C07D213/16
CPC分类号: A23L27/2054 , A23L27/2056 , A23V2002/00 , C07D213/28 , C07D213/32
摘要: in which R1, R2, R3, R4 R5, R6 are independently selected from the group consisting of H, methyl, ethyl, propyl, OH, OMe, OEt, COOH, COOR7, in which R7 is selected from linear or branched C1-C7 alkyl, and CONR8R9, in which R8 and R9 are independently selected from hydrogen and straight or branched C1-C4 alkyl; or any two adjacent substituents R2-R6 together form a ring of 5 or 6 members; and n is 1 or 0.
-
公开(公告)号:EP1871762A2
公开(公告)日:2008-01-02
申请号:EP06750555.2
申请日:2006-04-18
申请人: NEUROGEN CORPORATION
发明人: WHITEHOUSE, Darren , HU, Shaojing , ZHAO, He , GUO, Qin , WUSTROW, David , HAMMER, Jack , MAYNARD, George , MAO, Jianmin , FRINGLE, Wallace , YUAN, Jun , LI, Hongbin
IPC分类号: C07D401/04 , C07D403/04 , C07D401/14 , C07D417/14 , C07D403/14 , C07D413/14 , C07D405/12 , C07D401/12 , C07D403/12 , C07D417/04 , A61K31/497 , A61K31/53
CPC分类号: C07D403/14 , C07D213/28 , C07D213/61 , C07D213/74 , C07D239/42 , C07D239/54 , C07D241/12 , C07D241/20 , C07D241/24 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14
摘要: Compounds of Formula (I) are provided. In which the variables are as described herein. Such compounds may be used to modulate CBl activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CBl modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such Iigands for receptor localization studies and various in vitro assays.
-
-
-
-
-